^
Association details:
| Biomarker: | CD24 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
Published date:
05/25/2021
Excerpt:
The CD24 positive expression group had significant higher Complete Response (CR) rate than that with CD24 negative expression (44.4% vs 26.0%)...CD24 high expression was positively correlated with treatment response in ABC-DLBCL patients receiving R-CHOP.
DOI:
https://doi.org/10.2147/PGPM.S310816
